IL2 and melanoma: A two-armed phase II clinical trial in 69 patients suffering from stage IV melanoma concluded a significant increase in progression-free survival for patients receiving the L19-IL-2 plus dacarbazine combination therapy in comparison to chemotherapy alone [121].